Vesalius Biocapital

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception. With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financing rounds. Their companies are based in Europe allowing easy interaction with management. They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

Gaston Matthyssens

Managing Partner

Fei Tian

Principal

CW

Cees Wortel

Venture Partner Vesalius Biocapital Fund 3

46 past transactions

Mecuris GmbH

Series B in 2020
Mecuris GmbH develops and supplies individual and custom-made orthopedic aids. Its products include orthoses, prostheses, and equipment, such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and Mecuris solution platform. Mecuris GmbH was founded in 2016 and is based in Munich, Germany.

Scenic Biotech B.V.

Series A in 2022
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severe diseases.

Caresyntax

Series C in 2021
At caresyntax, your core mission is to bridge the variability gap of processes and outcomes in surgery and interventional radiology. We raise the surgical performance bar by empowering clinicians with actionable, enterprise-level data analytics.

Apitope

Series B in 2015
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology.

Caresyntax

Series C in 2021
At caresyntax, your core mission is to bridge the variability gap of processes and outcomes in surgery and interventional radiology. We raise the surgical performance bar by empowering clinicians with actionable, enterprise-level data analytics.

DEARhealth, Inc.

Series A in 2019
DEARhealth, Inc. operates as a health technology company which designs and develops SaaS based health care management platform for medical providers and health insurers. The company uses advanced data analytics to drive disease-specific, coordinated care pathways with streamlined provider workflows, patient apps, and organizational decision support. The company was founded in 2013 and is based in Beverly Hills, California.

Exact Imaging

Series C in 2017
Exact Imaging develops high-resolution micro-ultrasound systems for enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its micro-ultrasound system enables visualization and targeting of suspicious regions, in addition to performing systematic TRUS biopsies for prostate cancer imaging and the surrounding anatomy. The company also offers FusionVu micro-ultrasound/MRI fusion application to complement its ExactVu micro-ultrasound system for prostate imaging and biopsy. Exact Imaging was formerly known as Imagistx, Inc. and changed its name to Exact Imaging in March 2015. The company was founded in 2003 and is based in Markham, Canada.

Rejuvenate Biomed

Series B in 2021
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.

Memo Therapeutics AG

Series B in 2022
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Mecuris GmbH

Series A in 2019
Mecuris GmbH develops and supplies individual and custom-made orthopedic aids. Its products include orthoses, prostheses, and equipment, such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and Mecuris solution platform. Mecuris GmbH was founded in 2016 and is based in Munich, Germany.

Topas Therapeutics GmbH

Series B in 2021
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Genkyotex S.A.

Series D in 2015
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Ogeda

Private Equity Round in 2012
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.

Catalym

Series B in 2020
CATALYM GmbH develops immuno-oncology therapeutics. The company was founded in 2016 and is based in Munich, Germany.

Rejuvenate Biomed

Series A in 2021
Rejuvenate Biomed is a biomedical company researching the biology of aging & applying this knowledge to identify safe and well tolerated drugs to maintain and restore our natural cell resilience capacity improving the respons to age-related diseases.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Genkyotex S.A.

Series C in 2012
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Ncardia

Series A in 2014
Pluriomics is a Leiden (The Netherlands) based biotech company focused on development of fully functional human assay systems for use in drug discovery and development. Based on their novel proprietary methods for differentiation of stem cells they develop highly functional cell types like their Pluricyte Cardiomyocytes. They use these cells in combination with phenotypic assays to deliver high quality results.

OMEICOS Therapeutics

Series A in 2015
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

Trinean

Venture Round in 2008
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.

Amakem

Series A in 2011
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

Trinean

Venture Round in 2012
Trinean is a Belgium based technology provider, bringing micro-volume molecular spectroscopy to the next level by combining best in class analytical software with a highly standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University, Belgium and Imec Leuven, Belgium, the company commercializes UV/VIS spectrometers for biomolecule quantification. The DropSense™16 and DropSense™96, analyzing up to 16 and 96 samples resp., use microfluidic chips for standardized sample analysis (DropPlates™ and Slides). The Trinean platform is complemented with a software toolbox for improved data interpretation and lab-automation.

Genkyotex S.A.

Series C in 2011
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Activaero

Series A in 2009
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.

Genomic Vision

Series B in 2008
Genomic Vision is a biotechnology company that combines pioneering Molecular Combing, a proprietary single DNA molecule detection technology, with biomarker discovery to develop and commercialize novel genetic tests and research tools for life sciences. Genomic Vision’s products focus on DNA analysis and genetic testing in the fields of cancer, rare inherited disorders and pharmacogenomics.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

TROD Medical

Series B in 2013
Trod Medical S.A. operates as a medical equipment and surgical device manufacturer. The company was founded in 2006 and is based in Paris, France.

Complix

Series B in 2013
Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.

OMEICOS Therapeutics

Series C in 2018
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

FF Pharmaceuticals BV

Series A in 2013
FF Pharma, a biopharmaceutical company, develops anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The functions of CD40 in immune regulation suggest that the CD40 pathway may play a role in diseases in which anomalous immune responses, e.g. autoantibody production or chronic inflammation, are a feature.

Complix

Series A in 2010
Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.

OncoDNA SA

Series B in 2020
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.

SWORD Health

Seed Round in 2018
SWORD Health is a digital musculoskeletal (MSK) therapy provider. The company pairs licensed physical therapists with innovative technology to help people overcome their chronic and post-surgical pain faster and more cost-effectively. We’re on a mission to free two billion people from pain by making it simple for people to recover at home, without resorting to imaging, surgeries, or opioids. Since launching in 2015, SWORD Health has worked with insurers, health systems, and employers in Europe, Australia, and the U.S. to give thousands of people access to preventative, chronic, and post-surgical MSK care that gets results. SWORD Health has offices in New York City, Chicago, Salt Lake City, Sydney, and Porto.

Humedics GmbH

Series C in 2014
Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes. LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally.

Apitope

Series A in 2008
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology.

OMEICOS Therapeutics

Series B in 2017
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

Activaero

Series A in 2011
Activaero GmbH, a drug delivery company, engages in the research, development, manufacture, and marketing of controlled breathing technologies that are used for the delivery of inhaled therapeutic agents to the human lung and various lung regions. It offers AKITA, a controlled breathing device with smart card technology for the pulmonary delivery of inhaled therapeutics; and Watchhaler, an inhalation device tailored to the needs of children who need to take inhaled medication. The company also provides AKITA², a controlled breathing technology for the pulmonary delivery of inhaled therapeutics in the clinical trial setting; and LimiX, a first flow limitation valve that controls the flow rate. In addition, it offers measurement and diagnostic technologies for use in laboratory settings, including a system to measure the properties of aerosols in a minute. Further, the company provides contract development services for devices to use in clinical trials; and clinical trial logistics services. It markets its products through distributors. Activaero GmbH was founded in 2004 and is based in Gemunden, Germany. It also has locations in Munich, Germany; and Dublin, Ohio.

SWORD Health

Series B in 2021
SWORD Health is a digital musculoskeletal (MSK) therapy provider. The company pairs licensed physical therapists with innovative technology to help people overcome their chronic and post-surgical pain faster and more cost-effectively. We’re on a mission to free two billion people from pain by making it simple for people to recover at home, without resorting to imaging, surgeries, or opioids. Since launching in 2015, SWORD Health has worked with insurers, health systems, and employers in Europe, Australia, and the U.S. to give thousands of people access to preventative, chronic, and post-surgical MSK care that gets results. SWORD Health has offices in New York City, Chicago, Salt Lake City, Sydney, and Porto.

Ogeda

Series B in 2015
Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.

Ncardia

Series B in 2017
Pluriomics is a Leiden (The Netherlands) based biotech company focused on development of fully functional human assay systems for use in drug discovery and development. Based on their novel proprietary methods for differentiation of stem cells they develop highly functional cell types like their Pluricyte Cardiomyocytes. They use these cells in combination with phenotypic assays to deliver high quality results.

Tonic App S.A.

Venture Round in 2019
Tonic App is a B2C2B digital health company building a professional ecosystem for medical doctors. Tonic App helps medical doctors to diagnose and treat their patients by curating, for them, in a single mobile platform, the best professional resources from peers, publishers, regulatory bodies, recruiters, providers & the industry.

SWORD Health

Series A in 2020
SWORD Health is a digital musculoskeletal (MSK) therapy provider. The company pairs licensed physical therapists with innovative technology to help people overcome their chronic and post-surgical pain faster and more cost-effectively. We’re on a mission to free two billion people from pain by making it simple for people to recover at home, without resorting to imaging, surgeries, or opioids. Since launching in 2015, SWORD Health has worked with insurers, health systems, and employers in Europe, Australia, and the U.S. to give thousands of people access to preventative, chronic, and post-surgical MSK care that gets results. SWORD Health has offices in New York City, Chicago, Salt Lake City, Sydney, and Porto.

Forendo Pharma

Venture Round in 2019
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.The company's drugs are competent in tissue specific hormone mechanisms for the treatment of broader gynecological conditions and Fispemifene, a novel SERM, enabling medical companies to improve the treatment of male urological conditions and giving new opportunities to unmet needs in women's and men's health.

ProFibrix

Series B in 2011
ProFibrix B.V., a biotech company, creates, develops, and markets products for the hemostasis and regenerative medicine markets. Its products include Fibrocaps, a dry powder topical hemostat and tissue sealant based on a mixture of fibrinogen and thrombin, which stops acute and severe bleeding during surgery or in connection with trauma injury. The company also provides a sterilized single-use delivery device to deliver Fibrocaps to the target tissue area without the need to manipulate the wound in a surgical environment. It offers its products based on human fibrinogen, a natural blood protein for haemostasis, blood clotting, and tissue repair and healing. ProFibrix B.V. was founded in 2004

Topas Therapeutics GmbH

Series B in 2020
Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Forendo Pharma

Venture Round in 2018
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.The company's drugs are competent in tissue specific hormone mechanisms for the treatment of broader gynecological conditions and Fispemifene, a novel SERM, enabling medical companies to improve the treatment of male urological conditions and giving new opportunities to unmet needs in women's and men's health.